Plain-English translation of NCT06727617 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining a new immunotherapy drug called with standard chemoradiotherapy ( plus radiation) works better than chemoradiotherapy alone after cervical cancer surgery. The study focuses on patients whose cancer had certain high-risk features found during surgery that make recurrence more likely. Half the participants will receive the medication plus chemoradiotherapy, and half will receive chemoradiotherapy alone, to see which approach works better.
After cervical cancer surgery, some patients have features in their tumors that put them at higher risk of the cancer coming back. Doctors currently use radiation and to try to prevent this, but outcomes could still be better. This medication is being tested because it works differently — by helping the immune system fight cancer cells — and researchers hope combining it with standard treatment might improve survival and reduce recurrence.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the medication plus chemoradiotherapy or chemoradiotherapy alone. Both groups will undergo radiation and over several weeks as part of their cancer treatment after surgery. You will need to attend regular hospital or clinic visits for treatment administration and monitoring of side effects. The study will follow your health and recovery over time to compare how well each approach works.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~134 participants
Started
November 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maobin Meng, Dr.
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.